title: Transitional probability-based model for HPV clearance in HIV-1-positive adolescent females.
abstract: BACKGROUND
  HIV-1-positive patients clear the human papillomavirus (HPV) infection less frequently than HIV-1-negative. Datasets for estimating HPV clearance probability often have irregular measurements of HPV status and risk factors. A new transitional probability-based model for estimation of probability of HPV clearance was developed to fully incorporate information on HIV-1-related clinical data, such as CD4 counts, HIV-1 viral load (VL), highly active antiretroviral therapy (HAART), and risk factors (measured quarterly), and HPV infection status (measured at 6-month intervals).
  
  
  RESULTS
  Data from 266 HIV-1-positive and 134 at-risk HIV-1-negative adolescent females from the Reaching for Excellence in Adolescent Care and Health (REACH) cohort were used in this study. First, the associations were evaluated using the Cox proportional hazard model, and the variables that demonstrated significant effects on HPV clearance were included in transitional probability models. The new model established the efficacy of CD4 cell counts as a main clearance predictor for all type-specific HPV phylogenetic groups. The 3-month probability of HPV clearance in HIV-1-infected patients significantly increased with increasing CD4 counts for HPV16/16-like (p<0.001), HPV18/18-like (p<0.001), HPV56/56-like (p = 0.05), and low-risk HPV (p<0.001) phylogenetic groups, with the lowest probability found for HPV16/16-like infections (21.60±1.81% at CD4 level 200 cells/mm(3), p<0.05; and 28.03±1.47% at CD4 level 500 cells/mm(3)). HIV-1 VL was a significant predictor for clearance of low-risk HPV infections (p<0.05). HAART (with protease inhibitor) was significant predictor of probability of HPV16 clearance (p<0.05). HPV16/16-like and HPV18/18-like groups showed heterogeneity (p<0.05) in terms of how CD4 counts, HIV VL, and HAART affected probability of clearance of each HPV infection.
  
  
  CONCLUSIONS
  This new model predicts the 3-month probability of HPV infection clearance based on CD4 cell counts and other HIV-1-related clinical measurements.
authors.affiliation: Duke Cancer Institute, Duke University Medical Center, Durham, North Carolina, United States of America. julia.krauchanka@duke.edu
authors.forename: Julia
authors.initials: J
authors.lastname: Kravchenko
authors.forename: Igor
authors.initials: I
authors.lastname: Akushevich
authors.forename: Staci L
authors.initials: SL
authors.lastname: Sudenga
authors.forename: Craig M
authors.initials: CM
authors.lastname: Wilson
authors.forename: Emily B
authors.initials: EB
authors.lastname: Levitan
authors.forename: Sadeep
authors.initials: S
authors.lastname: Shrestha
mesh_terms: D000293:Adolescent; D000465:Algorithms; D052685:Alphapapillomavirus / Q000254:growth & development / Q000276:immunology / Q000502:physiology*; D018791:CD4 Lymphocyte Count; D060085:Coinfection; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000453:epidemiology / Q000276:immunology / Q000821:virology*; D015497:HIV-1 / Q000502:physiology*; D006801:Humans; D015994:Incidence; D008962:Models, Theoretical; D030361:Papillomavirus Infections / Q000150:complications / Q000453:epidemiology / Q000276:immunology / Q000821:virology*; D015995:Prevalence; D011336:Probability; D014762:Viral Interference / Q000502:physiology; D019562:Viral Load / Q000502:physiology / Q000706:statistics & numerical data